Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 1, 1996
[Study of serum CDDP concentrations in patients with advanced or recurrent adeno-or squamous cell carcinoma under combination chemotherapy of 5-FU (CIV) and low-dose CDDP (IV)]A Yagihashi, K Sasaki, K Hirata, et al.Investigational New Drugs|November 18, 2000
Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in JapanT Shirasaka, S Yamamitsu, A Tsuji, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 18, 2000
[Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU]T Shirasaka, S Yamamitsu, A Tsuji, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 3, 2000
[Current status of "low-dose cisplatin-5-FU therapy" for solid tumors (2nd report)--from a nationwide questionnaire on its adverse effects]T Toge, H Nakazato, M Nishiyama, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|November 30, 1999
[Combination chemotherapy of continuous infusion 5-FU and daily low-dose CDDP in colorectal carcinoma]T Furuhata, K Hirata, S Yamamitsu, et al.Clinical Oncology (Royal College of Radiologists (Great Britain))|November 15, 2006
Moderate neutropenia with S-1 plus low-dose cisplatin may predict a more favourable prognosis in advanced gastric cancerB Nakata, A Tsuji, Y Mitachi, et al.Journal of Hepato-Biliary-Pancreatic Surgery|January 9, 1999
Biochemical modulation therapy for pancreatic cancerK Hirata, M Mukaiya, S Yamamitsu, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 31, 1999
[Biochemical modulation of 5-FU--effect of low dose CDDP]K Hirata, S Yamamitsu, A Tsuji, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 1, 1997
[Combination chemotherapy of continuous infusion 5-fluorouracil and daily low-dose cisplatin in advanced gastrointestinal and lung adenocarcinoma]K Sasaki, K Hirata, R Denno, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|November 14, 1997
[Current status of low-dose CDDP. 5-FU therapy for solid malignant tumors--nationwide questionnaire survey]S Saji, K Aiba, H Araki, et al.Pageof 2